Effect of Chronic Supplementation of L-arginine in the Muscular Performance

Phase 4

Terminated

• Conditions: Muscular Fatigue
• Interventions: Drug: L-arginine aspartate (Targifor); Drug: Placebo L-arginine aspartate (Targifor)

• Registration Number: NCT00785811
• Lead Sponsor: Sanofi

Brief Summary

The primary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular fatigue of the quadriceps, expressed in terms of the Fatigue Resistance Factor (FRF). The secondary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular force the quadriceps.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-11-04
• Study First Submitted QC: 2008-11-04
• Study First Posted: 2008-11-05
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2011-03
• Last Update Submitted: 2011-03-15
• Last Update Posted: 2011-03-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	L-arginine aspartate (Targifor)	L-arginine aspartate (Targifor)
2	Placebo L-arginine aspartate (Targifor)	Placebo

Primary Outcome Measures

Name	Time	Method
Fatigue Resistance Factor (FRF)	Throughout the study

Secondary Outcome Measures

Name	Time	Method
Maximum force in Newton (N) and fast or explosive force	at time 90% of the maximum isometric force

Trial Locations

Locations (1)

Sanofi-Aventis Administrative Office; 🇧🇷 Sao Paulo, Brazil